Prospector Partners LLC Has $9.55 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Prospector Partners LLC grew its position in Hologic, Inc. (NASDAQ:HOLX) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,637 shares of the medical equipment provider’s stock after acquiring an additional 1,017 shares during the quarter. Prospector Partners LLC owned 0.06% of Hologic worth $9,551,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Innealta Capital LLC acquired a new position in Hologic in the second quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic in the 1st quarter worth approximately $37,000. Cranbrook Wealth Management LLC bought a new position in shares of Hologic during the 2nd quarter worth approximately $47,000. Mather Group LLC. acquired a new stake in Hologic in the 1st quarter valued at $48,000. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Stephens restated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a research note on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. Finally, Evercore ISI increased their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $87.60.

Hologic Stock Down 1.2 %

NASDAQ HOLX opened at $81.39 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67. The stock has a market capitalization of $18.99 billion, a P/E ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The stock has a fifty day moving average of $80.82 and a 200-day moving average of $77.12.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the firm posted $0.93 earnings per share. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts forecast that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.